SANOFI-AVENTIS (EPA:SAN) Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Transparency directive : regulatory news
11/12/2023 01:30